Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
Certara2026 年 2 月 2 日
Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®)
Discover population PK modeling made faster and easier with Phoenix NLME and Pirana in this…
Certara2026 年 1 月 30 日
Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®)
This on demand session demonstrates how Phoenix WinNonlin® and other tools work together within Phoenix®…
Certara2026 年 1 月 27 日
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
Certara2026 年 1 月 26 日
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
Certara2026 年 1 月 22 日
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy
Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…
Certara2026 年 1 月 22 日
